Skip to main content
. 2021 Jan 7;48(3):279–288. doi: 10.1111/1346-8138.15668

Table 2.

Summary of primary efficacy end‐point

Analysis population Sofpironium Vehicle Difference, % (95% CI) P *
Achievement of primary efficacy end‐point, % (no. of patients)
FAS 53.9% (76/141) 36.4% (51/140) 17.5% (6.02–28.93) 0.003
PPS 54.5% (72/132) 37.8% (48/127) 16.8% (4.78–28.72) 0.006

CI, confidence interval; FAS, full analysis set; PPS, per protocol set.

*

χ2‐Test.